Cargando…
Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2
Neutralizing agents against SARS-CoV-2 are urgently needed for the treatment and prophylaxis of COVID-19. Here, we present a strategy to rapidly identify and assemble synthetic human variable heavy (VH) domains toward neutralizing epitopes. We constructed a VH-phage library and targeted the angioten...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356808/ https://www.ncbi.nlm.nih.gov/pubmed/33082574 http://dx.doi.org/10.1038/s41589-020-00679-1 |
_version_ | 1783737011605078016 |
---|---|
author | Bracken, Colton J. Lim, Shion A. Solomon, Paige Rettko, Nicholas J. Nguyen, Duy P. Zha, Beth Shoshana Schaefer, Kaitlin Byrnes, James R. Zhou, Jie Lui, Irene Liu, Jia Pance, Katarina Zhou, Xin X. Leung, Kevin K. Wells, James A. |
author_facet | Bracken, Colton J. Lim, Shion A. Solomon, Paige Rettko, Nicholas J. Nguyen, Duy P. Zha, Beth Shoshana Schaefer, Kaitlin Byrnes, James R. Zhou, Jie Lui, Irene Liu, Jia Pance, Katarina Zhou, Xin X. Leung, Kevin K. Wells, James A. |
author_sort | Bracken, Colton J. |
collection | PubMed |
description | Neutralizing agents against SARS-CoV-2 are urgently needed for the treatment and prophylaxis of COVID-19. Here, we present a strategy to rapidly identify and assemble synthetic human variable heavy (VH) domains toward neutralizing epitopes. We constructed a VH-phage library and targeted the angiotensin-converting enzyme 2 (ACE2) binding interface of the SARS-CoV-2 Spike receptor-binding domain (Spike-RBD). Using a masked selection approach, we identified VH binders to two non-overlapping epitopes and further assembled these into multivalent and bi-paratopic formats. These VH constructs showed increased affinity to Spike (up to 600-fold) and neutralization potency (up to 1400-fold) on pseudotyped SARS-CoV-2 virus when compared to standalone VH domains. The most potent binder, a trivalent VH, neutralized authentic SARS-CoV-2 with half-maximal inhibitory concentration (IC(50)) of 4.0 nM (180 ng/mL). A cryo-EM structure of the trivalent VH bound to Spike shows each VH domain engaging an RBD at the ACE2 binding site, confirming our original design strategy. |
format | Online Article Text |
id | pubmed-8356808 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
record_format | MEDLINE/PubMed |
spelling | pubmed-83568082021-08-11 Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2 Bracken, Colton J. Lim, Shion A. Solomon, Paige Rettko, Nicholas J. Nguyen, Duy P. Zha, Beth Shoshana Schaefer, Kaitlin Byrnes, James R. Zhou, Jie Lui, Irene Liu, Jia Pance, Katarina Zhou, Xin X. Leung, Kevin K. Wells, James A. Nat Chem Biol Article Neutralizing agents against SARS-CoV-2 are urgently needed for the treatment and prophylaxis of COVID-19. Here, we present a strategy to rapidly identify and assemble synthetic human variable heavy (VH) domains toward neutralizing epitopes. We constructed a VH-phage library and targeted the angiotensin-converting enzyme 2 (ACE2) binding interface of the SARS-CoV-2 Spike receptor-binding domain (Spike-RBD). Using a masked selection approach, we identified VH binders to two non-overlapping epitopes and further assembled these into multivalent and bi-paratopic formats. These VH constructs showed increased affinity to Spike (up to 600-fold) and neutralization potency (up to 1400-fold) on pseudotyped SARS-CoV-2 virus when compared to standalone VH domains. The most potent binder, a trivalent VH, neutralized authentic SARS-CoV-2 with half-maximal inhibitory concentration (IC(50)) of 4.0 nM (180 ng/mL). A cryo-EM structure of the trivalent VH bound to Spike shows each VH domain engaging an RBD at the ACE2 binding site, confirming our original design strategy. 2020-10-20 2021-01 /pmc/articles/PMC8356808/ /pubmed/33082574 http://dx.doi.org/10.1038/s41589-020-00679-1 Text en http://www.nature.com/authors/editorial_policies/license.html#termsUsers may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms |
spellingShingle | Article Bracken, Colton J. Lim, Shion A. Solomon, Paige Rettko, Nicholas J. Nguyen, Duy P. Zha, Beth Shoshana Schaefer, Kaitlin Byrnes, James R. Zhou, Jie Lui, Irene Liu, Jia Pance, Katarina Zhou, Xin X. Leung, Kevin K. Wells, James A. Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2 |
title | Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2 |
title_full | Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2 |
title_fullStr | Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2 |
title_full_unstemmed | Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2 |
title_short | Bi-paratopic and multivalent VH domains block ACE2 binding and neutralize SARS-CoV-2 |
title_sort | bi-paratopic and multivalent vh domains block ace2 binding and neutralize sars-cov-2 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8356808/ https://www.ncbi.nlm.nih.gov/pubmed/33082574 http://dx.doi.org/10.1038/s41589-020-00679-1 |
work_keys_str_mv | AT brackencoltonj biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT limshiona biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT solomonpaige biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT rettkonicholasj biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT nguyenduyp biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT zhabethshoshana biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT schaeferkaitlin biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT byrnesjamesr biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT zhoujie biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT luiirene biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT liujia biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT pancekatarina biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT zhouxinx biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT leungkevink biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 AT wellsjamesa biparatopicandmultivalentvhdomainsblockace2bindingandneutralizesarscov2 |